A vertically integrated U.S. crude heparin extraction facility co-located with a Tier-1 pork processor, exporting purified API to a domestic finished-dose manufacturer or licensing internationally. The thesis maps the federal funding stack (BARDA BioMaP active parenteral API solicitation, DPA Title III, IRA Section 48D), the demand floor (SAPIR + DoD, VA, SNS direct procurement), and the structural moat (BIOSECURE Act + EO 14293 dual-test — including the FOUL determination that unmasks Smithfield BioScience as Chinese state-controlled).
— The thesis
Every hospital in the United States uses heparin every day. It is the universal anticoagulant for cardiac surgery, the standard prophylactic for hospitalized patients at any risk of thrombosis, and the indispensable additive for every indwelling intravenous catheter. The U.S. consumes 80 to 100 metric tons of heparin sodium API per year and depends on China for 60 to 80 percent of that supply.
This is not a vulnerability that emerged. It is one that was created — through a 20-year offshoring cascade that began in the 1990s when U.S. extractors closed because porcine mucosa was cheaper to ship to China than to retain domestically. By 2008, that dependency caused the Heparin Sodium Contamination Crisis: Chinese suppliers substituted oversulfated chondroitin sulfate for genuine heparin. The contamination killed 81 Americans and triggered the largest pharmaceutical recall in FDA history. The dependency was never fixed.
"The FOUL analysis is the analytical centerpiece of ISR-001. Smithfield BioScience operates a Virginia heparin extraction facility that appears domestic. Beneficial ownership tracing through WH Group to Yunnan State-owned Assets Supervision and Administration Commission reveals it is Chinese state-controlled. The one entity that appears to provide domestic supply fails the BIOSECURE Act ownership test. The domestic production gap is complete."
The investment thesis turns this dependency into a commercial opportunity. A vertically integrated U.S. crude heparin extraction facility, co-located with a Tier-1 Iowa pork processor for guaranteed mucosa feedstock, exporting purified heparin sodium API to a domestic finished-dose manufacturer or licensing internationally. Net equity $15M. Federal offset $56M (72% of base CapEx). Equity IRR 35–50%. Base-case exit $530M at 10× EBITDA.
— Deliverables
| Investment thesis + 10 appendices | 27-page PDF · 12 sections · 72-page appendix set. Appendix A: MTS scoring, FOUL methodology, 22/25 rationale. Appendix B: Comparable transactions — Bioibérica, Pfizer Wilson, Hepalink IPO, exit multiple framework. Appendix C: Bibliography. Appendix D: MTS Framework Reference — FOUL methodology, ten-paper SSRN programme. Appendix E: Regulatory pathway — PreCheck, ANDA prioritization, post-2008 quality regime. Appendix F: Market coverage. Appendix G: Pricing, cost position, SECMap ownership chain (Smithfield → WH Group → Yunnan SASAC). Appendix H: Government contracts — BARDA BioMaP active solicitation, DPA III, SAPIR, VA/DLA/TRICARE/SNS/IHS. Appendix I: Operations, automation, quality. Appendix J: Iowa economic impact — $10–18M/yr new agricultural revenue from porcine mucosa currently exported to China at near-zero value. |
|---|---|
| 5-page executive summary | PDF + DOCX — the thesis in 5 pages. Suitable for firm-internal circulation before purchase decision. |
| Financial model | 14-sheet xlsx workbook — 10-year cash flow, CapEx schedule, federal funding stack, IRR/NPV/payback, sensitivity tables, multi-scenario exit waterfall. |
| Primary-source fact sheet | 11-sheet xlsx — 30 cited sources, FDA recall data, DoD/SNS procurement, BARDA BioMaP terms, comparable transaction multiples. |
| Analyst follow-up | 30 days direct email access · one 60-minute call at your convenience |
| Exclusivity | Sold once · permanent removal from catalog · 18-month right of first refusal on any refresh |
— De-risked under EO 14293
The BIOSECURE Act (December 2025, NDAA) disqualifies Chinese heparin producers and — critically — Smithfield BioScience by adversary UBO ownership. EO 14293 (May 2025) requires domestic production for federal premium-tier contracting. After the FOUL determination, zero current heparin API suppliers pass both tests. ISR-001 is the only available path to federal premium-tier compliance.
Unlike ISR-002 and ISR-003 which apply to general solicitations, ISR-001 can file immediately against an active February 2026 parenteral drug API solicitation — program ceiling $200M, heparin sodium directly eligible. The active solicitation eliminates one full funding cycle of waiting. An ISR-001 white paper can be submitted in Month 1 of project formation.
An ISR-001 facility hits every PreCheck priority criterion: sterile injectable, shortage-list resident, documented Chinese dependency, U.S.-sourced API from co-located porcine processing. ANDA prioritization follows for domestic finished-dose holders who reference the ISR-001 Type II DMF.
— Preview
A 5-page substantive extract covering the dependency framework, federal architecture, investment profile, and the full table of contents — sent directly to your work email.
If $50,000 isn't the right entry point right now, two lower-friction options keep you engaged with the firm and the thesis pipeline.
Sold once. Leaves the catalog permanently. Full package + 30 days analyst follow-up.
Purchase60 minutes on this thesis or any related question. $1,500 credits to this purchase.
Book intake callEvery future thesis 30 days before public catalog. 10–20% discount on any thesis purchase.
Plans